WO1999061039A3 - Novel composition for modulating ischemic cell death - Google Patents

Novel composition for modulating ischemic cell death Download PDF

Info

Publication number
WO1999061039A3
WO1999061039A3 PCT/EP1999/003520 EP9903520W WO9961039A3 WO 1999061039 A3 WO1999061039 A3 WO 1999061039A3 EP 9903520 W EP9903520 W EP 9903520W WO 9961039 A3 WO9961039 A3 WO 9961039A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
ischemic cell
inhibitor
novel composition
kinase
Prior art date
Application number
PCT/EP1999/003520
Other languages
French (fr)
Other versions
WO1999061039A2 (en
Inventor
Patrik Htun
Wolfgang Schaper
Miroslav Barancik
Original Assignee
Max Planck Gesellschaft
Patrik Htun
Wolfgang Schaper
Miroslav Barancik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Patrik Htun, Wolfgang Schaper, Miroslav Barancik filed Critical Max Planck Gesellschaft
Publication of WO1999061039A2 publication Critical patent/WO1999061039A2/en
Publication of WO1999061039A3 publication Critical patent/WO1999061039A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Abstract

Described is the modulation of ischemic cell death. In particular, pharmaceutical compositions are provided comprising an inhibitor of p38 kinase and/or a nucleic acid molecule encoding said inhibitor which are particularly useful for treating, preventing and/or delaying ischemic cell death. Furthermore, methods for treating, preventing and/or delaying ischemic cell death comprising contacting organs, tissue or cells with an inhibitor of p38 kinase and/or a nucleic acid molecule encoding said inhibitor are described. In addition, methods and uses employing agents that activate p38 kinase for the treatment of tumors are provided.
PCT/EP1999/003520 1998-05-22 1999-05-21 Novel composition for modulating ischemic cell death WO1999061039A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98109370.1 1998-05-22
EP98109370 1998-05-22

Publications (2)

Publication Number Publication Date
WO1999061039A2 WO1999061039A2 (en) 1999-12-02
WO1999061039A3 true WO1999061039A3 (en) 2000-02-17

Family

ID=8231985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003520 WO1999061039A2 (en) 1998-05-22 1999-05-21 Novel composition for modulating ischemic cell death

Country Status (1)

Country Link
WO (1) WO1999061039A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260033T3 (en) * 1999-07-02 2006-11-01 Stuart A. Lipton USE OF P38 MAPK INHIBITORS IN OPHTHALMIC EFERMADADES.
DE10042137A1 (en) * 2000-08-28 2002-03-14 Florian Lang sgk2 and sgk3 as diagnostic and therapeutic targets
DE10219545A1 (en) * 2002-04-26 2003-11-06 Lang Florian Regulation of apoptosis
KR101032281B1 (en) * 2003-03-03 2011-05-06 플로리안 랑 Sgk1 as diagnostic and therapeutic target
WO2006021896A2 (en) * 2004-08-27 2006-03-02 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2006109196A2 (en) * 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
US20060281791A1 (en) * 2005-04-29 2006-12-14 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998027098A1 (en) * 1996-12-18 1998-06-25 Vertex Pharmaceuticals Incorporated SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
WO1999000357A1 (en) * 1997-06-27 1999-01-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
WO1999016457A2 (en) * 1997-10-01 1999-04-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for treating, preventing and/or delaying ischemic cell death

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998027098A1 (en) * 1996-12-18 1998-06-25 Vertex Pharmaceuticals Incorporated SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
WO1999000357A1 (en) * 1997-06-27 1999-01-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
WO1999016457A2 (en) * 1997-10-01 1999-04-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for treating, preventing and/or delaying ischemic cell death

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLERK A ET AL: "The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs).", FEBS LETTERS, (1998 APR 10) 426 (1) 93-6., XP002125896 *
KUMMER J L ET AL: "Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 AUG 15) 272 (33) 20490-4., XP002125897 *
MA X L ET AL: "Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion.", CIRCULATION, (1999 APR 6) 99 (13) 1685-91., XP000857740 *
MACKAY K ET AL: "An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 MAR 5) 274 (10) 6272-9., XP002125898 *
NAGARKATTI D S ET AL: "Role of p38 MAP kinase in myocardial stress.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, (1998 AUG) 30 (8) 1651-64., XP000857687 *

Also Published As

Publication number Publication date
WO1999061039A2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
YU40203A (en) Ortho-substituted nitrogen-containing bisaril compounds used as potassium channel inhibitors
BRPI0510663A (en) at least one chemical entity, composition, methods for modulating cenp-e kinesin activity, inhibiting cenp-e, and treating a cell proliferative disease, and, use of at least one chemical entity
EP2221376A3 (en) Antisense modulation of superoxide dismutase 1, soluble expression
AU7585598A (en) Raf kinase inhibitors
WO1993021942A3 (en) Use of mmp inhibitors
BR0112638A (en) Preservation and storage medium for biological materials
AU3262497A (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
WO2001083547A3 (en) Anti-inflammatory compounds and uses thereof
WO2000071493A3 (en) INHIBITORS OF FACTOR Xa
BR9805544A (en) Use of a compound.
JO2283B1 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
PT996409E (en) COMPOSITION FOR DELAYING CAPILLARY GROWTH AND CORRESPONDING USES
DE69912479D1 (en) 4- AND 5-ALKYNYLOX INDOLES AND 4- AND 5-ALKENYLOX INDOLES
TR200200883T2 (en) 2-substituted 1,1-biphenyl-2-carbonamides, manufacturing methods, use as drugs
WO2000071515A3 (en) INHIBITORS OF FACTOR Xa
WO1999061039A3 (en) Novel composition for modulating ischemic cell death
WO2002011762A3 (en) Methods and compositions for modulating tumor growth
BR0016547A (en) Composition for the modulation and inhibition of vascular permeability (vp)
EP1304123A3 (en) Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
BR9913190A (en) Modulation of multiple lineage protein kinase
EP1144690A4 (en) Antisense modulation of cellular inhibitor of apoptosis-2 expression
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
EP1163373A4 (en) Antisense modulation of cellular inhibitor of apoptosis-1 expression
CA2330025A1 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA